Galapagos NV (GLPG):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3499)
◆英語タイトル:Galapagos NV (GLPG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3499
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:91
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines. The company’s clinical pipeline include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn’s disease, Phase 2 and 3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. It conducts clinical trials for various investigational drugs. The company works in collaboration with pharma companies for its research activities. It has its presence in the Netherlands, Belgium, France and Croatia. Galapagos is headquartered in Mechelen, Belgium.

Galapagos NV (GLPG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Galapagos NV, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
ProQR Therapeutics and Galapagos Enter into Research Agreeement 14
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 15
Pharnext Enters into Research Agreement with Galapagos 16
Gilead Sciences Enters into Co-Development Agreement with Galapagos 17
Calchan Enters into Research Partnership with Galapagos 18
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 19
AbbVie Expands its Agreement with Galapagos 20
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 22
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 23
Licensing Agreements 25
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Equity Offering 32
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 32
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 33
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 34
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 35
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 36
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 37
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 39
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 40
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD425 Million in Private Placement of Shares 44
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 46
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD74.5 Million in Private Placement of Shares 48
Galapagos Raises USD240 Million in Public Offering of Shares 50
Galapagos to Raise Funds through Private Placement 52
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 53
Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 54
Galapagos Completes Private Placement Of Shares For US$70 Million 55
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 57
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 58
Asset Transactions 59
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 59
Acquisition 60
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 63
Galapagos NV – Key Competitors 64
Galapagos NV – Key Employees 65
Galapagos NV – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Recent Developments 67
Financial Announcements 67
Aug 02, 2018: Productive first half-year at Galapagos 67
Apr 25, 2018: Galapagos reports first quarter 2018 results 68
Oct 26, 2017: Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline 69
Jul 27, 2017: Solid financials support R&D progress 70
Jul 27, 2017: Galapagos: Solid financials support R&D progress 71
Apr 27, 2017: Galapagos reports first quarter 2017 results 72
Feb 23, 2017: Galapagos reports strong financial results and newsflow-rich pipeline 73
Corporate Communications 75
Jan 17, 2017: Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer 75
Product News 76
05/15/2017: Seven abstracts on filgotinib accepted by EULAR 2017 76
Clinical Trials 77
May 01, 2018: Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients 77
Feb 17, 2018: Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego 78
Sep 27, 2017: MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients 80
Jul 05, 2017: Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis 82
May 07, 2017: Galapagos presents three posters on filgotinib in Crohn’s disease at DDW 2017 83
Apr 29, 2017: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI 84
Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 85
Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 86
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 87
Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 88
Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn’s disease 89
Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91

List of Tables
Galapagos NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 14
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 15
Pharnext Enters into Research Agreement with Galapagos 16
Gilead Sciences Enters into Co-Development Agreement with Galapagos 17
Calchan Enters into Research Partnership with Galapagos 18
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 19
AbbVie Expands its Agreement with Galapagos 20
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 22
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 23
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 32
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 33
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 34
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 35
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 36
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 37
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 39
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 40
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD425 Million in Private Placement of Shares 44
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 46
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD74.5 Million in Private Placement of Shares 48
Galapagos Raises USD240 Million in Public Offering of Shares 50
Galapagos to Raise Funds through Private Placement 52
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 53
Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 54
Galapagos Completes Private Placement Of Shares For US$70 Million 55
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 57
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 58
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 59
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 63
Galapagos NV, Key Competitors 64
Galapagos NV, Key Employees 65
Galapagos NV, Subsidiaries 66

List of Figures
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Galapagos NV (GLPG):製薬・医療:M&Aディール及び事業提携情報(Galapagos NV (GLPG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆